Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles.
Ibon Martínez-ArranzChiara BruzzoneMazen NoureddinRuben Gil-RedondoItziar MincholéMaider BizkarguenagaEnara ArretxeMarta Iruarrizaga-LejarretaDavid Fernández-RamosFernando Lopitz-OtsoaRebeca MayoNieves EmbadeElizabeth NewberryBettina MittendorfLaura Izquierdo-SánchezVaclav SmidJorge ArnoldPaula IruzubietaYlenia Pérez CastañoMarcin KrawczykUrko M MarigortaMartine C MorrisonRobert KleemannAntonio Martín-DuceLiat HayardenyLibor VítekRadan BrůhaRocío Aller de la FuenteJavier CrespoManuel RomeroJesus M BanalesMarco ArreseKenneth CusiElisabetta BugianesiSamuel KleinShelly C LuQuentin Mark AnsteeOscar MilletNicholas O DavidsonCristina AlonsoJose M MatoPublished in: Hepatology (Baltimore, Md.) (2022)
Metabolomic signatures identify three NAFLD subgroups, independent of histological disease severity. These signatures align with known CVD and genetic risk factors, with subtype A exhibiting a lower CVD risk profile. This may account for the variation in hepatic versus cardiovascular outcomes, offering clinically relevant risk stratification.